Therapeutic Efficacy of SQ641-NE against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 587-589

  Nikonenko, Boris ^a   Reddy, Venkata M ^a   Bogatcheva, Elena ^a   Protopopova, Marina ^a   Einck, Leo ^a   Nacy, Carol A ^a  

^a SEQUELLA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; SQ 641; TOCOFERSOLAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CONCENTRATION TIME CURVE; ARTICLE; BACTERIOSTASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; DRUG LUNG LEVEL; DRUG SPLEEN LEVEL; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF QUANTITATION; LOWEST LIMIT OF QUANTITATION; MACROPHAGE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANOEMULSION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; FEMALE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84891526259     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01254-13     Document Type: Article

References (20)

1. Kimura K, Bugg TD. 2003. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat. Prod. Rep. 20:252-273. http://dx.doi.org/10.1039/b202149h
2. Bugg TD, Lloyd AJ, Roper DI. 2006. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect. Disord. Drug Targets 6:85-106. http://dx.doi.org/10.2174/ 187152606784112128
3. Yamaguchi H, Sato S, Yoshida S, Takada K, Itoh M. 1986. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J. Antibiot. 39:1047-1053.
4. Muramatsu Y, Ishii MM, Inukai M. 2003. Studies on novel bacterial translocase I inhibitors, A-500359s. II. Biological activities of A-500359 A, C, D and G. J. Antibiot. 56:253-258. http://dx.doi.org/10.7164/antibiotics.56.253
5. Hotoda H, Kaneko M, Inukai M, Muramatsu Y, Utsui Y, Ohya S. 2007. Antibacterial compound. U.S. patent 7157442 B2. Sankyo Company, Ltd., Tokyo, Japan
6. Hotoda H, Furukawa M, Daigo M, Murayama K, Kaneko M, Muramatsu Y, Ishii MM, Miyakoshi S, Takatsu T, Inukai M, Kakuta M, Abe T, Harasaki T, Fukuoka T, Utsui Y, Ohya S. 2003. Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin. Bioorg. Med. Chem. Lett. 13:2829-2832. http://dx.doi.org/10.1016/S0960-894X(03) 00596-1
7. Hotoda H, Daigo M, Furukawa M, Murayama K, Hasegawa CA, Kaneko M, Muramatsu Y, Ishii MM, Miyakoshi S, Takatsu T, Inukai M, Kakuta M, Abe T, Fukuoka T, Utsui Y, Ohya S. 2003. Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds. Bioorg. Med. Chem. Lett. 13:2833-2836. http://dx.doi.org/10.1016/ S0960-894X(03)00597-3
8. Dubuisson T, Bogatcheva E, Krishnan MY, Collins MT, Einck L, Nacy CA, Reddy VM. 2010. In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria. J. Antimicrob. Chemother. 65:2590-2597. http://dx.doi.org/10.1093/jac/dkq372
9. Reddy VM, Einck L, Nacy CA. 2008. In vitro antimycobacterial activity of capuramycin analogues. Antimicrob. Agents Chemother. 52:719-721. http://dx.doi.org/10.1128/AAC.01469-07
10. Koga T, Fukuoka T, Doi N, Harasaki T, Inoue H, Hotoda H, Kakuta M, Muramatsu M, Yamamura N, Hoshi M, Hirota T. 2004. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J. Antimicrob. Chemother. 54:755-760. http://dx.doi.org/10.1093/jac/dkh417.
11. Nikonenko BV, Reddy VM, Protopopova M, Bogatcheva E, Einck L, Nacy CA. 2009. Activity of SQ641, a capuramycin analog in murine model of tuberculosis. Antimicrob. Agents Chemother. 53:3138-3139. http://dx.doi.org/10.1128/AAC.00366- 09
12. Bogatcheva E, Dubuisson T, Protopopova M, Einck L, Nacy CA, Reddy VM. 2011. Chemical modification of capuramycins to enhance antibacterial activity. J. Antimicrob. Chemother. 66:578-587. http://dx.doi.org/10.1093/jac/dkq495
13. Nikonenko BV, Samala R, Reddy V, Einck L, Nacy CA. 2008. Activity of SQ641, a capuramycin analog in murine model of tuberculosis (TB), abstr. F1-1162, p 289-290. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC
14. Reddy VM, Bogatcheva E, Protopopova M. 2008. Enhancement of intracellular activity of capuramycin (CM) analogue SQ641 against M. tuberculosis (MTB), abstr. C1-3851, p146. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC
15. Reddy VM, Bogatcheva E, Einck L, Nacy CA. 2011. Nunoemulsion formulation enhances intracellular activity of capuramycin analogues against Mycobacterium tuberculosis. Drug Del. Lett. 1:150-158
16. Snewin VA, Gares MP, Gaora PO, Hasan Z, Brown IN, Young DB. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67:4586-4593
17. Eklund D, Welin A, Schon T, Stendahl O, Huygen K, Lerm M. 2010. Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis. Clin. Vaccine Immunol. 17: 513-517. http://dx.doi.org/10.1128/CVI.00446-09
18. Constantinides PP, Chaubal MV, Shorr R. 2008. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Del. Rev. 60:757-767. http://dx.doi.org/10.1016/j.addr.2007.10.013
19. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert RO, Martin F, Muller-Govemann C. 2010. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res. 27:1469-1486. http://dx.doi.org/10.1007/s11095-010-0130-x.
20. Liu H, Wang L. 2006. Lipid emulsions for total parenteral nutrition (TPN) use and as carriers of lipid-soluble drugs, p 301-312. In Shahidi F (ed), Nutraceutical and specialty lipids and their coproducts. CRC Press, Boca Raton, FL